|
業務類別
|
Biotechnology |
|
業務概覽
|
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates. |
| 公司地址
| 1000 Skokie Boulevard, Suite 350, Wilmette, IL, USA, 60091 |
| 電話號碼
| +1 847 388-0349 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.monopartx.com |
| 員工數量
| 22 |
| Dr. Patrice P. Rioux,M.D.,PhD |
Acting Chief Medical Officer |
-- |
30/04/2026 |
| Mr. Quan Anh Vu |
Chief Financial Officer, Secretary and Treasurer |
美元 305.00K |
30/04/2026 |
| Dr. Chandler D. Robinson, M. Sc.,M.B.A.,M.D. |
Chief Executive Officer and Director |
美元 700.00K |
30/04/2026 |
| Mr. Andrew J. Cittadine |
Chief Operating Officer |
美元 440.00K |
30/04/2026 |
| Ms. Susan Rodriguez |
Chief Commercial and Strategy Officer |
-- |
30/04/2026 |
|
|
| Mr. Arthur J. Klausner, M.B.A. |
Independent Director |
30/04/2026 |
| Dr. Christopher M. Starr,PhD |
Executive Chairman of the Board |
30/04/2026 |
| Ms. Kim R. Tsuchimoto |
Director |
30/04/2026 |
| Mr. Raymond William Anderson, M.B.A.,M.S. |
Independent Director |
30/04/2026 |
| Dr. Chandler D. Robinson, M. Sc.,M.B.A.,M.D. |
Chief Executive Officer and Director |
30/04/2026 |
| Ms. Nicole Sweeny |
Independent Director |
30/04/2026 |
| Ms. Lavina Talukdar, C.F.A. |
Independent Director |
30/04/2026 |
|
|
|
|
